BiotechTube

Duloxetine + Bupropion

ApprovedWithdrawn
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Major Depressive Disorder

Conditions

Major Depressive Disorder

Trial Timeline

Oct 15, 2020 → May 30, 2023

NCT ID
NCT04388189

About Duloxetine + Bupropion

Duloxetine + Bupropion is a approved stage product being developed by Alto Neuroscience for Major Depressive Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04388189. Target conditions include Major Depressive Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Major Depressive Disorder were approved

Approved (20) Terminated (0) Active (0)
✅Mirtazapine TabletsSun PharmaceuticalApproved
✅DuloxetineEli LillyApproved
✅duloxetineEli LillyApproved
✅DuloxetineEli LillyApproved
✅duloxetine hydrochlorideEli LillyApproved
✅DuloxetineEli LillyApproved
✅DuloxetineEli LillyApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04388189ApprovedWithdrawn

Competing Products

20 competing products in Major Depressive Disorder

See all competitors
ProductCompanyStageHype Score
Duloxetine HydrochlorideEli LillyPre-clinical
26
LY2216684Eli LillyPhase 1
29
LY2216684Eli LillyPhase 1
29
DuloxetineEli LillyPhase 3
40
LY2216684 + DigoxinEli LillyPhase 1
29
Duloxetine + ParoxetineEli LillyPhase 3
40
Duloxetine + placeboEli LillyPhase 3
40
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
35
FK949EAstellas PharmaPhase 1
29
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
35
FK949EAstellas PharmaPhase 1
29
FK949EAstellas PharmaPhase 1
29
FK949EAstellas PharmaPhase 1
29
Mirtazapine TabletsSun PharmaceuticalApproved
43
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
35
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
39
Pramipexole ER + EscitalopramCiplaPhase 2
42
LY2216684 + SertralineEli LillyPhase 1
29
LY2216684 + Placebo + LorazepamEli LillyPhase 1
29
LY2216684 + SSRIEli LillyPhase 3
40